Lenvatinib Mesilate Capsules is an oral multi-target kinase inhibitor, primarily targeting VEGFR1-4, FGFR1-3, PDGFRα/β, c-Kit, and RET. It inhibits tumor angiogenesis, suppresses tumor cell growth, and modulates the tumor immune microenvironment. Clinically, it is used to treat unresectable hepatocellular carcinoma (uHCC). The global multi-center REFLECT study showed significant efficacy of Lenvatinib in treating uHCC. It has been included as a first-line treatment for advanced liver cancer in countries such as China, Japan, and the United States.